Abstract:We describe the total synthesis of tutuilamide A, a potent porcine pancreatic elastase (PPE) inhibitor and a representative member of 3-amino-6-hydroxy-2-piperidone (Ahp) cyclodepsipeptide family, isolated from marine cyanobacteria. The Ahp unit serves as a pharmacophore and the adjacent 2-amino-2-butenoic acid (Abu) is a main driver of the selectivity among serine proteases. We adapted our previous convergent strategy to generate the macrocycle, common with lyngbyastatin 7 and related elastase inhibitors, and then appended the tutuilamide A-specific side chain bearing a vinyl chloride. Tutuilamide A and lyngbyastatin 7 were evaluated side by side for the inhibition of the disease-relevant human neutrophil elastase (HNE). Tutuilamide A and lyngbyastatin 7 were approximately equipotent against HNE, while tutuilamide A was previously shown to be more active against PPE compared with lyngbyastatin 7, further demonstrating that the side chain provides opportunities to not only modulate potency but also selectivity among proteases of the same function from different organisms. Profiling of tutuilamide A against mainly human serine proteases revealed high selectivity for HNE (IC50 0.73 nM) and pleiotropic activity against kallikrein 7 (KLK7, IC50 5.0 nM), without affecting other kallikreins, similarly to lyngbyastatin 7 (IC50 0.85 nM for HNE and 3.1 nM for KLK7). A comprehensive molecular docking study for elastases and KLK7 afforded deeper insight into the intricate differences between inhibitor interactions with HNE and PPE, accounting for the differential activities for both compounds. The synthesis and molecular studies serve as a proof-of-concept that the macrocyclic scaffold can be diversified to fine-tune the activity of serine protease inhibitors.

Targeted Library of Phosphonic-Type Inhibitors of Human Neutrophil Elastase

Identification and characterization of aptameric inhibitors of human neutrophil elastase

Natural Compounds as Inhibitors of Human Neutrophil Elastase

Investigating Polypharmacology Through Targeting Known Human Neutrophil Elastase Inhibitors to Proteinase 3

Utilization of computational methods for the identification of new natural inhibitors of human neutrophil elastase in inflammation therapy

Peptide Human Neutrophil Elastase Inhibitors from Natural Sources: An Overview

Non-peptide-based Fluorogenic Small-Molecule Probe for Elastase.

Synthesis and biological evaluation of nigranoic acid esters as novel human neutrophil elastase inhibitors

Identification of novel human neutrophil elastase inhibitors from dietary phytochemicals using in silico and in vitro studies

Structure-activity relationships of dihydropyrimidone inhibitors against native and auto-processed human neutrophil elastase

Ahp-Cyclodepsipeptides as tunable inhibitors of human neutrophil elastase and kallikrein 7: Total synthesis of tutuilamide A, serine protease selectivity profile and comparison with lyngbyastatin 7

Studies on Human Neutrophil Elastase and Its Inhibitors

Enzymatic, structural, and biophysical characterization of a single‐domain antibody (VHH) selectively and tightly inhibiting neutrophil elastase and exhibiting favorable developability properties

Characterization of Intra- vs. Extracellular Inhibition

A Potent and Selective Inhibitor for the UBLCP1 Proteasome Phosphatase.

Robust anti-inflammatory activity of genistein against neutrophil elastase: a microsecond molecular dynamics simulation study

Use of protease substrate specificity screening in the rational design of selective protease inhibitors with unnatural amino acids: Application to HGFA, matriptase, and hepsin

A Multifunctional Protease Inhibitor To Regulate Endolysosomal Function

Terpenoids as Human Neutrophil Elastase (HNE) Inhibitors: a comprehensive review of Natural Anti‐inflammatory Isoprenoids

Nanomedicine platform for targeting activated neutrophils and neutrophil-platelet complexes using an α1-antitrypsin-derived peptide motif